Haemonetics has gotten torched over the last six months - since October 2024, its stock price has dropped 20.1% to $63.39 per share. This was partly due to its softer quarterly results and might have investors contemplating their next move.
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,
and over the past six months, the industry has pulled back by 8.4%. This drop was disappointing since the S&P 500 stood firm.
HAEMONETICS CORP/MASS has caught the attention as a great value stock. NYSE:HAE excels in profitability, solvency, and liquidity, all while being very reasonably priced.
Looking back on medical devices & supplies - specialty stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Globus Medical (NYSE:GMED) and its peers.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at STAAR Surgical (NASDAQ:STAA) and the best and worst performers in the medical devices & supplies - specialty industry.
HAEMONETICS CORP/MASS is a hidden gem, featuring undervaluation and robust fundamentals. NYSE:HAE showcases decent financial health and profitability, coupled with an attractive price.
Blood products company Haemonetics (NYSE:HAE). fell short of the market’s revenue expectations in Q4 CY2024 as sales rose 3.7% year on year to $348.5 million. Its non-GAAP profit of $1.19 per share was 1.7% above analysts’ consensus estimates.
